Literature DB >> 14632382

The disutility of advance directives: we know the problems, but are there solutions?

Daniel P Hickey1.   

Abstract

Advance directives (ADs) are recognized in some form by the laws of every state. Despite the availability of ADs for more than twenty years, few adults have completed any type of AD document. Even when ADs are validly executed, physicians routinelyfail to honor patients' wishes. The lack of communication between physicians and patients may be the primary reason why AD completion rates remain so low. The failure to honor an AD may stem from the physician's belief that to honor a directive would not be in the patient's best interest. The adoption and enforcement by all states of the Uniform Health-Care Decisions Act, recognition of a physician's ethical duty to assist patients in AD formulation, and routine third-party payor reimbursement to physicians for their role in patients' advance care planning will encourage and facilitate the completion and subsequent honoring of patients' directives.

Entities:  

Keywords:  Death and Euthanasia; Legal Approach; Uniform Health-Care Decisions Act

Mesh:

Year:  2003        PMID: 14632382

Source DB:  PubMed          Journal:  J Health Law        ISSN: 1526-2472


  3 in total

1.  Variations in Physician Orders for Life-Sustaining Treatment Program across the Nation: Environmental Scan.

Authors:  Aluem Tark; Mansi Agarwal; Andrew W Dick; Patricia W Stone
Journal:  J Palliat Med       Date:  2019-02-21       Impact factor: 2.947

2.  How would terminally ill patients have others make decisions for them in the event of decisional incapacity? A longitudinal study.

Authors:  Daniel P Sulmasy; Mark T Hughes; Richard E Thompson; Alan B Astrow; Peter B Terry; Joan Kub; Marie T Nolan
Journal:  J Am Geriatr Soc       Date:  2007-11-20       Impact factor: 5.562

3.  Determinants of completion of advance directives: a cross-sectional comparison of 649 outpatients from private practices versus 2158 outpatients from a university clinic.

Authors:  Jochen Pfirstinger; Bernhard Bleyer; Christian Blum; Michael Rechenmacher; Christoph H Wiese; Hans Gruber
Journal:  BMJ Open       Date:  2017-12-21       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.